MicroStrategy, Portland General Electric And Other Big Stocks Moving Lower In Thursdays Pre-Market Session
| ITOS Stock | USD 8.15 0.25 3.16% |
Slightly above 55% of Iteos Therapeutics' private investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Iteos Therapeutics suggests that some traders are interested. Iteos Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Iteos Therapeutics' earnings reports, geopolitical events, and overall market trends.
Iteos |
U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Thursday.
Read at benzinga.com
 |
Iteos Therapeutics Fundamental Analysis
We analyze Iteos Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Iteos Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Iteos Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Iteos Therapeutics is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Iteos Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Iteos Therapeutics stock to make a market-neutral strategy. Peer analysis of Iteos Therapeutics could also be used in its relative valuation, which is a method of valuing Iteos Therapeutics by comparing valuation metrics with similar companies.
Peers
Iteos Therapeutics Related Equities
| DSGN | Design Therapeutics | 7.94 | ||||
| AMLX | Amylyx Pharmaceuticals | 6.14 | ||||
| SANA | Sana Biotechnology | 3.64 | ||||
| ABOS | Acumen Pharmaceuticals | 2.70 | ||||
| KYMR | Kymera Therapeutics | 1.71 | ||||
| ERAS | Erasca | 1.48 | ||||
| TERN | Terns Pharmaceuticals | 1.41 | ||||
| BPMC | Blueprint Medicines | 1.32 | ||||
| APLS | Apellis Pharmaceuticals | 0.90 | ||||
| GLUE | Monte Rosa | 0.84 | ||||
| RVMD | Revolution Medicines | 0.27 | ||||
| MLTX | MoonLake Immunotherapeuti | 0.22 | ||||
| TCRX | Tscan Therapeutics | 0.65 | ||||
| DAWN | Day One | 0.94 | ||||
| ANNX | Annexon | 1.64 |
Additional Tools for Iteos Stock Analysis
When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.